Publication date: May 20, 2019 Therapeutic failures in cancer therapy are often associated with metabolic plasticity. The use of metabolic modulators as anti-cancer agents has been effective in correcting metabolic ... Read more

Publication date: May 20, 2019 Neuroblastoma RAS viral oncogene homolog is a commonly mutated oncogene in melanoma, and therapeutic targeting of neuroblastoma RAS viral oncogene homolog has proven difficult. We ... Read more

Publication date: May 20, 2019 Tumor heterogeneity affects the efficacy of anticancer treatment as tumor subclones with distinct molecular patterns may be present within one tumor, leading to differing sensitivities ... Read more

Publication date: May 21, 2019 Antigen-presenting cells expand antigen-specific T cells ex vivo and in vivo for tumor immunotherapy, but are time-consuming to generate and, as live cells, raise biosafety ... Read more

Publication date: May 21, 2019 The present study aimed to investigate the antitumor effects of an intratumoral injection of dendritic cells (DCs) overexpressing interleukin-12 (IL-12) on melanoma. DCs, isolated from ... Read more

Publication date: May 21, 2019 Melanoma is the deadliest form of skin cancer, affecting men more frequently and severely than women. Although recent studies suggest that differences in activity of ... Read more

Publication date: May 22, 2019 MicroRNA-21 (miR-21) is a potential therapeutic target for melanoma. Whether miR-21 inhibitor affects the anti-cancer activity of doxorubicin assisted by c(RGDyK)-modified liposome (DLN) in melanoma ... Read more

Publication date: May 22, 2019 Emerging data support the rationale of combined therapies in advanced melanoma. Specifically, the combined use of drugs with different mechanisms of action can reduce the ... Read more